Mucin Binding Lectin Imaging Agents for Colonic Polyp Imaging
Posted Feb 29 2008 4:00pm
Description of Invention: Available for licensing and commercial development is an imaging agent specific for colonic polyps that overexpress glycoprotein alpha-L-fucose containing mucins. Colon cancer is the second leading cause of cancer related deaths in the United States. The legume protein Ulex europaeus agglutinin I (UEA-1) has shown high specificity to alpha-L-fucose glycoproteins. Colonic mucosal neoplasia and/or polyps with high surface expression of alpha-L-fucosyl terminal residues can be specifically targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would eliminate a patient’s need to drink harsh enema/contrast solutions prior to CT imaging.
Applications:
Colon cancer
Cancer imaging
Contrast agents
CT colonography
Inventors: Ronald M Summers (CC) Jianwu Xie (CC) Celeste A Roney (CC)
C Roney et al. Glycoprotein expression by adenomatous polyps of the colon. Proc. SPIE, Vol 6916, 691601 (2008); Published online 12 March 2008, doi:10.1117/12.769224.
SD O’Connor et al. Oral contrast adherence to polyps on CT colonography. J Comput Assist Tomogr. 2006 Jan-Feb;30(1):51-57. [ PubMed abs ]
For Additional Information Please Contact: Jeffrey James Ph.D. NIH Office of Technology Transfer 100 N. Charles St., 5th Floor, Baltimore, MD 21201 United States Email: anos@mail.nih.gov
Description of Invention:
Available for licensing and commercial development is an imaging agent specific for colonic polyps that overexpress glycoprotein alpha-L-fucose containing mucins. Colon cancer is the second leading cause of cancer related deaths in the United States. The legume protein Ulex europaeus agglutinin I (UEA-1) has shown high specificity to alpha-L-fucose glycoproteins. Colonic mucosal neoplasia and/or polyps with high surface expression of alpha-L-fucosyl terminal residues can be specifically targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would eliminate a patient’s need to drink harsh enema/contrast solutions prior to CT imaging.
Applications:
Inventors:
Ronald M Summers (CC)
Jianwu Xie (CC)
Celeste A Roney (CC)
Patent Status:
HHS, Reference No. E-254-2007/0
US, Application No. 61/064,086 filed 15 Feb 2008
US, Application No. 12/371,472 filed 13 Feb 2009
Relevant Publication:
Licensing Status:
Available for licensing.
Portfolios:
Devices/Instrumentation
Devices/Instrumentation - Diagnostics
Nanotechnology
For Additional Information Please Contact:
Jeffrey James Ph.D.
NIH Office of Technology Transfer
100 N. Charles St., 5th Floor,
Baltimore, MD 21201
United States
Email: anos@mail.nih.gov
Ref No: 1725
Updated: 03/2008